• clonoSEQ
    NGS MRD Monitoring

    View the technical summary
  • A myeloma patient's perspective on MRD

    Watch Tim’s story
  • Adaptive Assist

    Learn More

What is MRD?

Even if you are responding well to treatment or are in remission, a small number of cancer cells can remain in your body, and may cause your disease to return. This is called measurable (or minimal) residual disease, also known as MRD.

learn more about MRD

With MRD testing, you and your doctor have a personalized way to track—and talk about—your body’s individual response to treatment.

learn more about MRD

News and Updates

clonoSEQ, from Adaptive Biotechnologies, is a next-generation sequencing assay with existing Medicare coverage to monitor for minimal residual disease (MRD) in multiple myeloma and B-cell acute lymphoblastic leukemia. The newest Medicare coverage is for chronic lymphocytic leukemia (CLL), which takes effect immediately.

View Press Release

May, 2020
Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing.

View Press Release

April, 2020
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19.

View Press Release

This page is intended for use by healthcare professionals of the United States.

clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

Contact Us

Make an inquiry to learn more about our products.

Request Information